7-5999116-G-A
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000535.7(PMS2):c.697C>T(p.Gln233*) variant causes a stop gained change. The variant allele was found at a frequency of 0.00000682 in 1,613,882 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000535.7 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 152046Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251492Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135920
GnomAD4 exome AF: 0.00000616 AC: 9AN: 1461836Hom.: 0 Cov.: 33 AF XY: 0.00000413 AC XY: 3AN XY: 727230
GnomAD4 genome AF: 0.0000132 AC: 2AN: 152046Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74254
ClinVar
Submissions by phenotype
not provided Pathogenic:5
- -
- -
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 19132747, 20186688, 27694994, 26681312, 28874130, 27435373, 25512458, 30787465, 31332305, 33087929, 29922827, 35534704, 26110232, 29345684, Chelal2022[article]) -
- -
- -
Lynch syndrome 4 Pathogenic:4
- -
ACMG classification criteria: PVS1, PS4, PM2 -
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
_x000D_ Criteria applied: PVS1, PS4 -
Lynch syndrome Pathogenic:3
The c.697C>T;p.(Gln233*) variant creates a premature translational stop signal in the PMS2 gene. It is expected to result in an absent or disrupted protein product -PVS1. This sequence change has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 91362; PMID: 19132747; PMID: 20186688; PMID: 27435373) - PS4. The variant is present at low allele frequencies population databases (rs587779343 – gnomAD 0.0001061%; ABraOM no frequency - http://abraom.ib.usp.br) - PM2_supporting. The variant was identified in an individual with a highly specific phenotype for the condition (PMID: 19132747, 27435373) - PP4. In summary, the currently available evidence indicates that the variant is pathogenic -
Coding sequence variation resulting in a stop codon -
The p.Gln233X variant in PMS2 has been previously reported in >15 individuals with PMS2-associated cancers (Rossi 2017, van der Klift 2016, Susswein 2016, Suerink 2016, ten Broeke 2015, Niessen 2009) and has been detected in 3/129188 of European chromosomes by gnomAD (https://gnomad.broadinstitute.org). This variant was classified as Pathogenic on September 5, 2013 by the ClinGen-approved InSiGHT expert panel (Variation ID 91362). This nonsense variant leads to a premature termination codon at position 233, which is predicted to lead to a truncated or absent protein. Loss of function of the PMS2 gene is an established disease mechanism in autosomal dominant Lynch syndrome. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant Lynch syndrome. ACMG/AMP Criteria applied: PVS1, PM2, PS4. -
Hereditary cancer-predisposing syndrome Pathogenic:2
This variant changes 1 nucleotide in exon 6 of the PMS2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with Lynch syndrome (PMID: 16472587, 19132747, 25512458, 26110232, 27435373, 28874130) and breast/ovarian cancer (PMID: 27153395, 29345684, 33471991; DOI: 10.1101/2021.04.15.21255554). This variant has been identified in 3/282860 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of PMS2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
The p.Q233* pathogenic mutation (also known as c.697C>T), located in coding exon 6 of the PMS2 gene, results from a C to T substitution at nucleotide position 697. This changes the amino acid from a glutamine to a stop codon within coding exon 6. This alteration was first reported in an individual with a uterine sarcoma diagnosed at 52 years and colorectal carcinoma (exhibiting microsatellite instability) diagnosed at 62 and 63 years (Niessen RC et al. Genes Chromosomes Cancer 2009 Apr;48:322-9). It has since been reported in multiple families with Lynch syndrome associated cancers (ten Broeke SW et al. J. Clin. Oncol. 2015 Feb;33:319-25; van der Klift HM et al. Hum. Mutat. 2016 11;37(11):1162-1179; Rossi BM et al. BMC Cancer 2017 Sep;17(1):623). Furthermore, this alteration has been shown to result in nonsense mediated mRNA decay by RT-PCR (van der Klift HM et al. Hum. Mutat. 2010 May;31:578-87). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Hereditary nonpolyposis colon cancer Pathogenic:1
Variant summary: PMS2 c.697C>T (p.Gln233X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 8e-06 in 251542 control chromosomes. c.697C>T has been reported in the literature in individuals affected with clinical features of PMS2-related conditions (example, Niessen_2009, van der Klift_2016, van der Klift_2010, Susswein_2016). The following publications have been ascertained in the context of this evaluation (PMID: 19132747, 20186688, 26681312, 27435373). ClinVar contains an entry for this variant (Variation ID: 91362). Based on the evidence outlined above, the variant was classified as pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gln233*) in the PMS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PMS2 are known to be pathogenic (PMID: 21376568, 24362816). This variant is present in population databases (rs587779343, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with Lynch syndrome and suspected Lynch syndrome (PMID: 19132747, 20186688, 25512458, 26110232, 27435373). ClinVar contains an entry for this variant (Variation ID: 91362). RNA analysis performed to evaluate the impact of this premature translational stop signal on mRNA splicing indicates it does not significantly alter splicing (internal data). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at